InflaRx (IFRX) Operating Expenses (2016 - 2026)
InflaRx (IFRX) posted Operating Expenses of -$8.7 million for Q1 2026, down 110.62% sequentially from $82.2 million in Q4 2025, and up 38.7% YoY from -$6.3 million in Q1 2025.
InflaRx (IFRX) Operating Expenses (2016 - 2026) Analysis & Trends
InflaRx has reported Operating Expenses for 11 years, with the latest figure at -$8.7 million in Q1 2026.
- Quarterly Operating Expenses rose 38.7% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.9 million (up 6.82% YoY) and the FY2025 annual result came in at -$382.6 million, down 192.22% from the prior year.
- Operating Expenses eased to -$8.7 million in Q1 2026 per IFRX's latest filing, from $82.2 million in the prior quarter.
- Over five years, Operating Expenses peaked at $104.0 million in Q4 2023 and troughed at -$53456.5 billion in Q4 2022.
- A 5-year average of -$3774.6 billion and a median of -$14.2 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 71215830.26% in 2022, then surged 100.0% in 2023.
- Over 5 years, Operating Expenses stood at -$53456.5 billion in 2022, then soared by 100.0% to $104.0 million in 2023, then slipped by 11.16% to $92.4 million in 2024, then retreated by 11.03% to $82.2 million in 2025, then sank by 110.62% to -$8.7 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered -$8.7 million, $82.2 million, and -$11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | -8.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.73 Mn |
| Dec 31, 2025 | 82.20 Mn |
| Sep 30, 2025 | -11.72 Mn |
| Jun 30, 2025 | -11.87 Mn |
| Mar 31, 2025 | -14.24 Mn |
| Dec 31, 2024 | 92.39 Mn |
| Sep 30, 2024 | -17.19 Mn |
| Jun 30, 2024 | -14.26 Mn |
| Mar 31, 2024 | -13.41 Mn |
| Dec 31, 2023 | 104.00 Mn |
| Sep 30, 2023 | -12.81 Mn |
| Jun 30, 2023 | -15.75 Mn |
| Mar 31, 2023 | -19.69 Mn |
| Dec 31, 2022 | -53,456.49 Bn |
| Sep 30, 2022 | -10,712.55 Bn |
| Jun 30, 2022 | -16.57 Mn |
| Mar 31, 2022 | -16.68 Mn |
| Dec 31, 2021 | -54,547.53 Bn |
| Sep 30, 2021 | -15.04 Mn |
| Jun 30, 2021 | -16.86 Mn |